Expert Outlook: Eli Lilly and Co Through The Eyes Of 25 Analysts

Jul 24, 2024 · Analysts have recently evaluated Eli Lilly and Co and provided 12-month price targets. The average target is $930.96, accompanied by a high estimate of $1025.00 and a …

$930.96
OFF

Expert Outlook: Eli Lilly And Co Through The Eyes Of 25 Analysts

2 weeks from now

Jul 24, 2024 · Analysts have recently evaluated Eli Lilly and Co and provided 12-month price targets. The average target is $930.96, accompanied by a high estimate of $1025.00 and a …

businessinsider.com

$955.64
OFF

Beyond The Numbers: 25 Analysts Discuss Eli Lilly Stock

2 weeks from now

Aug 12, 2024 · Analysts have recently evaluated Eli Lilly and provided 12-month price targets. The average target is $955.64, accompanied by a high estimate of $1125.00 and a low …

nasdaq.com

$964.46
OFF

A Glimpse Into The Expert Outlook On Eli Lilly Through 28 Analysts

2 weeks from now

Sep 9, 2024 · Analysts have set 12-month price targets for Eli Lilly, revealing an average target of $964.46, a high estimate of $1125.00, and a low estimate of $884.00.

nasdaq.com

$635.88
OFF

The Latest Analyst Ratings For Eli Lilly | Markets Insider

2 weeks from now

Jan 23, 2024 · Analysts have set 12-month price targets for Eli Lilly, revealing an average target of $635.88, a high estimate of $722.00, and a low estimate of $535.00.

businessinsider.com

83%
OFF

Eli Lilly & Co. Research & Ratings | LLY - Barron's

2 weeks from now

Eli Lilly & Co. research and ratings by Barron's. View LLY revenue estimates and earnings estimates, as well as in-depth analyst breakdowns. ... 25.83%. Day Range 784.86 - 800.00. 52 …

barrons.com

$930.96
OFF

Expert Outlook: Eli Lilly And Co Through The Eyes Of 25 Analysts

2 weeks from now

Analysts have recently evaluated Eli Lilly and Co and provided 12-month price targets. The average target is $930.96, accompanied by a high estimate of $1025.00 and a low estimate of …

capedge.com

25%
OFF

Is Eli Lilly A Buy? Analyst Confidence Grows For 2025 - MarketBeat

2 weeks from now

Nov 5, 2024 · Eli Lilly's price pullback is an opportunity worth 25%, with analysts' sentiment firming around the $1000 level. ... Regarding the guidance, the company trimmed its outlook …

marketbeat.com

25%
OFF

Eli Lilly: Recent Pullback Opens Buy Window As Stock Prepares For …

2 weeks from now

Nov 6, 2024 · Eli Lilly's price pullback presents investors with an opportunity. The stock has a healthy 25% upside from critical support targets. Despite tepid results, analysts' consensus is …

investing.com

32%
OFF

Eli Lilly: Unveils Its 2024 Forecasts And 2025 Ambitions

2 weeks from now

9 hours ago · Eli Lilly forecasts worldwide sales for 2024 of around $45 billion, up 32% on the previous year. ... Eli Lilly Eyes $2.5 Billion Deal for Scorpion Therapeutics ... Eli Lilly and …

marketscreener.com

$717
OFF

Eli Lilly's SWOT Analysis: Stock Soars On Diabetes Drug Success, Eyes ...

2 weeks from now

1 day ago · Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $717.9 billion, has been making waves in the biopharmaceutical industry with …

investing.com

7%
OFF

Eli Lilly Shares Tumble After Cutting Its Sales Outlook. What It Means ...

2 weeks from now

4 hours ago · Shares plunged 7% after management said demand for its popular GLP-1 drugs did not meet expectations.

cnbc.com

$717
OFF

Eli Lilly's SWOT Analysis: Stock Soars On Diabetes Drug Success, Eyes ...

2 weeks from now

23 hours ago · Eli Lilly and Company (NYSE: LLY), a leading pharmaceutical giant with a market capitalization of $717.9 billion, has been making waves in the biopharmaceutical industry with …

investing.com

7%
OFF

Stock Market Today: Dow Pops, Nasdaq Slips As Focus Turns To CPI ...

2 weeks from now

2 hours ago · Shares of Eli Lilly were a standout in the session, dropping over 7% and on track for their worst day since 2021 after the company said fourth quarter sales of its weight-loss drug …

yahoo.com

$3
OFF

Lilly Cuts Q4 Revenue View Below Market, Lifts FY24 Outlook; Sees ...

2 weeks from now

8 hours ago · Lilly now expects approximately $3.5 billion for Mounjaro and $1.9 billion for Zepbound. In total, non-incretin revenue grew by 20 percent. However, the company's …

businessinsider.com

32%
OFF

Eli Lilly Issues 2025 Revenue Forecast Ahead Of Market Estimates

2 weeks from now

9 hours ago · Investing.com -- Eli Lilly and Company (NYSE: LLY) has projected its full-year global revenue for 2024 to reach around $45 billion, marking a 32% increase from the prior …

investing.com

28%
OFF

Lilly Reports Strong Fourth-Quarter 2023 ... - Eli Lilly And Company

2 weeks from now

Feb 6, 2024 · Revenue in Q4 2023 increased 28%. New Products (i) revenue grew by $2.19 billion to $2.49 billion in Q4 2023, led by Mounjaro and Zepbound. Growth Products (ii) …

lilly.com

$32.53
OFF

Expert Outlook: Exelixis Through The Eyes Of 19 Analysts

2 weeks from now

Dec 17, 2024 · Analysts have set 12-month price targets for Exelixis, revealing an average target of $32.53, a high estimate of $39.00, and a low estimate of $27.00.

nasdaq.com

FAQs about Expert Outlook: Eli Lilly and Co Through The Eyes Of 25 Analysts Coupon?

What is the average price target for Eli Lilly & Co?

The average target is $930.96, accompanied by a high estimate of $1025.00 and a low estimate of $840.00. This current average has increased by 4.14% from the previous average price target of $893.92. In examining recent analyst actions, we gain insights into how financial experts perceive Eli Lilly and Co. ...

How much does Eli Lilly cost?

Analysts have set 12-month price targets for Eli Lilly, revealing an average target of $635.88, a high estimate of $722.00, and a low estimate of $535.00. Observing a downward trend, the current average is 2.4% lower than the prior average price target of $651.50. ...

How do analysts evaluate Eli Lilly & Co (ell) stock?

Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Eli Lilly and Co compared to the broader market. Price Targets: Understanding forecasts, analysts offer estimates for Eli Lilly and Co's future value. ...

Is Eli Lilly stock a good buy?

The average target predicts an increase of 26.10% from the current stock price of 777.53. The average analyst rating for Eli Lilly stock from 22 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market. ...

How do financial analysts perceive Eli Lilly & Co?

The perception of Eli Lilly and Co by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets. Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. ...

Should you buy Eli Lilly & Company?

MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list. While Eli Lilly and Company currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys. ...